Anxiety symptom remission is associated with genetic variation of PTPRZ1 among patients with major depressive disorder treated with escitalopram
Anxiety symptom remission is associated with genetic variation of PTPRZ1 among patients with major depressive disorder treated with escitalopram
复制标题
接受艾司西酞普兰治疗的重度抑郁症患者焦虑症状缓解与 PTPRZ1 遗传变异相关
DOI：
10.1097/fpc.0000000000000437
复制
发表时间：
2021-06
影响因子：
2.6
通讯作者：
Tian-Mei Si
中科院分区：
文献类型：
--
作者：
Yun-Ai Su;Chad A Bousman;Qi Liu;Xiao-Zhen Lv;Ji-Tao Li;Jing-Yu Lin;Xin Yu;Li Tian;Tian-Mei Si
补充数字内容可在文本中找到。抗抑郁反应的全基因组分析表明，最初与精神分裂症风险相关的基因也可能成为选择性5-羟色胺再摄取抑制剂（SSRI）疗效的有希望的候选基因。蛋白酪氨酸磷酸酶，受体型，zeta-1（PTPRZ 1）先前已被证明与精神分裂症有关，但尚未研究其作为抗抑郁药疗效的预测因子。本研究的主要目的是评估SSRI介导的抑郁和焦虑症状缓解是否与中国重性抑郁障碍（MDD）患者的特定PTPRZ 1变异相关。方法对两个独立队列进行调查，第一个样本（N = 344）接受SSRI（即，氟西汀、舍曲林、西酞普兰、艾司西酞普兰、氟伏沙明或帕罗西汀）8周。第二个样本（N = 160）仅接受艾司西酞普兰治疗8周。使用两个队列基线后8周的汉密尔顿抑郁和汉密尔顿焦虑评定量表评分确定缓解状态。在两个队列中对5种PTPRZ 1变体（rs 12154537、rs6466810、rs6466808、rs6955395和rs 1918031）进行基因分型。结果在队列2中，焦虑症状缓解与PTPRZ 1 rs 12154537（P = 0.004）和G-G-G-G单倍型（rs 12154537-rs6466810-rs6466808-rs6955395; P = 0.005）显著相关，但在队列1（混合使用SSRI）中与此无关。与抑郁症状缓解的关联在多次测试的校正中没有存活下来。结论PTPRZ 1基因变异可作为艾司西酞普兰介导的抑郁症患者焦虑症状缓解的标志物。
Supplemental Digital Content is available in the text. Objectives Genome-wide analyses of antidepressant response have suggested that genes initially associated with risk for schizophrenia may also serve as promising candidates for selective serotonin reuptake inhibitor (SSRI) efficacy. Protein tyrosine phosphatase, receptor-type, zeta-1 (PTPRZ1) has previously been shown to be associated with schizophrenia, but it has not been investigated as a predictor of antidepressant efficacy. The main objective of the study was to assess whether SSRI-mediated depressive and anxiety symptom remission in Chinese patients with major depressive disorder (MDD) are associated with specific PTPRZ1 variants. Methods Two independent cohorts were investigated, the first sample (N = 344) received an SSRI (i.e. fluoxetine, sertraline, citalopram, escitalopram, fluvoxamine, or paroxetine) for 8 weeks. The second sample (N = 160) only received escitalopram for 8 weeks. Hamilton Depression and Hamilton Anxiety Rating Scale scores at 8-weeks post-baseline in both cohorts were used to determine remission status. Five PTPRZ1 variants (rs12154537, rs6466810, rs6466808, rs6955395, and rs1918031) were genotyped in both cohorts. Results Anxiety symptom remission was robustly associated with PTPRZ1 rs12154537 (P = 0.004) and the G–G–G–G haplotype (rs12154537–rs6466810–rs6466808–rs6955395; P = 0.005) in cohort 2 but not cohort 1 (mixed SSRI use). Associations with depressive symptom remission did not survive correction for multiple testing. Conclusions These findings suggest that PTPRZ1 variants may serve as a marker of escitalopram-mediated anxiety symptom remission in MDD.
登录
查看更多内容
影响因子：
2.6
作者：
Yun-Ai Su;Ji‐Tao Li;Wen Dai;Xuemei Liao;Li Dong;T. Lu;C. Bousman;T. Si
通讯作者：
Yun-Ai Su;Ji‐Tao Li;Wen Dai;Xuemei Liao;Li Dong;T. Lu;C. Bousman;T. Si
影响因子：
11
作者：
Buxbaum, J. D.;Georgieva, L.;O'Donovan, M. C.
通讯作者：
O'Donovan, M. C.
影响因子：
7.6
作者：
Hannestad, Jonas;DellaGioia, Nicole;Bloch, Michael
通讯作者：
Bloch, Michael
影响因子：
4.4
作者：
Lv X;Si T;Wang G;Wang H;Liu Q;Hu C;Wang J;Su Y;Huang Y;Jiang H;Yu X
通讯作者：
Yu X
影响因子：
17.7
作者：
Trivedi, MH;Rush, AJ;Fava, M
通讯作者：
Fava, M